Summary
5-Fluorouracil (5-FU) and 5′-deoxy-5-fluorouridine (5′-DFUR), a prodrug of 5-FU, are anticancer agents activated by thymidine phosphorylase (TP). Transfecting the human TP cDNA into cancer cells in order to sensitize them to these pyrimidine antimetabolites may be an important approach in human cancer gene therapy research. In this study, an expression vector containing the human TP cDNA (pcTP5) was transfected into LS174T human colon carcinoma cells. Eight stable transfectants were randomly selected and analysed. The cytotoxic effects of 5-FU and 5′-DFUR were higher in TP-transfected cells as compared to wild-type cells. The maximal decreases in the IC50 were 80-fold for 5-FU and 40-fold for 5′-DFUR. The increase in sensitivity to these pyrimidines of TP-transfected cells significantly correlated with the increase in both TP activity and TP expression. Transfected clone LS174T-c2 but not wild-type cells exhibited formation of [3H]FdUMP from [3H]5-FU. In addition the LS174T-c2 clone enhanced the cytotoxic effect of 5′-DFUR, but also that of 5-FU, towards co-cultured parental cells. For both anti-cancer agents, this bystander effect did not require cell–cell contact. These results show that both 5-FU or 5′-DFUR could be used together with a TP-suicide vector in cancer gene therapy.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.
Chen, C. Y., Chang, Y. N., Ryan, P., Linscott, M., McGarrity, G. J. & Chiang, Y. L. (1995). Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the ‘bystander effect’. Hum Gene Ther 6: 1467–1476.
Chen, L. & Waxman, D. J. (1995). Intratumoral activation and enhanced chemotherapeutic effect of oxazophosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 55: 581–589.
Chu, E., Lai, G. M., Zinn, S. & Allegra, C. J. (1990). Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA. Mol Pharmacol 38: 410–417.
Cohen, A. M., Minsky, B. D. & Schilsky, R. L. (1993). Colon cancer. In Cancer, Principles and Practices of Oncology, 4th edn, Devita VT, Hellman S and Rosenberg SA (eds), pp. 929–977. JB Lippincott: Philadelphia
Denning, C. & Pitts, J. D. (1997). Bystander effect of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 8: 1825–1835.
Desgranges, C., Razaka, G. & Rabaud, H. (1981). Catabolism of thymidine in human blood platelets – purification and properties of thymidine phosphorylase. Biochim Biophys Acta 654: 211–218.
Elias, L. & Crismann, H. A. (1988). Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 48: 4868–4873.
Evrard, A., Vian, L., Aubert, C. & Cano, J. P. (1996). An in vitro nucleoside analog screening method for cancer gene therapy. Cell Biol Toxicol 12: 345–350.
Evrard, A., Cuq, P., Robert, B., Vian, L., Pèlegrin, A. & Cano, J. P. (1999). Enhancement of 5-fluorouracil cytotoxicity by human thymidine phosphorylase expression in cancer cells: in vitro and in vivo study. Int J Cancer 80: 465–470.
Fick, J., Barker, FG II, Dazin, P., Westphale, E. M., Beyer, E. C. & Israel, M. A. (1995). The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 92: 11071–11075.
Fox, S. B., Moghaddam, A., Westwood, M., Turley, H., Bicknell, R., Gatter, K. C. & Harris, A. L. (1995). Platelet-derived endothelial cell growth factor thymidine phosphorylase expression in normal tissues – an immunohistochemical study. J Pathol 176: 183–190.
Fox, S. B., Engels, K., Comley, M., Whitehouse, R. M., Turley, H., Gatter, K. C. & Harris, A. L. (1997). Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol 8: 271–275.
Freeman, S. M., Abboud, C. M., Whartenby, K. A., Packmann, C. H., Koeplin, D. S., Moolten, F. L. & Abraham, G. N. (1993). The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274–5283.
Friedkin, M. & Roberts, D. (1953). The enzymatic synthesis of nucleosides. Thymidine phosphorylase in mammalian tissue. J Biol Chem 207: 245–256.
Grem, J. L. & Fischer, P. H. (1986). Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res 46: 6191–6199.
Griffiths, L. & Stratford, I. J. (1997). Platelet derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer 76: 689–693.
Haraguchi, M., Furukawa, T., Sumizawa, T. & Akiyama, S. (1993). Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res 53: 5680–5682.
Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibells, S. & Richard, C. A. (1993). In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 53: 4619–4626.
Huber, B. E., Austin, E. A., Richards, C. A., Davis, S. T. & Good, S. S. (1994). Metabolism of 5-fluorocytosine in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91: 8302–8306.
Ishitsuka, H., Miwa, M., Takemoto, K., Fukuoka, K., Itoga, A. & Maruyama, H. B. (1980). Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Jpn J Cancer Res 71: 112–123.
Kato, Y., Matsukawa, S., Muraoka, R. & Tanigawa, N. (1997). Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br J Cancer 75: 506–511.
Krenitsky, T. A. (1968). Pentosyl transfer machanisms of the mammalian nucleoside phosphorylase. J Biol Chem 243: 2871–2875.
Lonn, U., Lonn, S., Nylen, U. & Winblad, G. (1989). 5-Fluoropyrimidine-induced DNA damage in human colon adenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole. Cancer Res 49: 1085–1089.
Luccioni, C., Beaumatin, J., Bardot, V. & Lefrancois, D. (1994). Pyrimidine nucleotide metabolism in human colon carcinomas: comparison of normal tissues, primary tumors and xenografts. Int J Cancer 58: 517–522.
Mader, R. M., Sieder, A. E., Braun, J., Rizovski, B., Kalipciyan, M., Mueller, M. W., Jakesz, R., Rainer, H. & Steger, G. G. (1997). Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidines resistance in colon cancer in vitro. Biochem Pharmacol 54: 1233–1242.
Miyadera, K., Sumizawa, T., Haraguchi, M., Yoshida, H., Konstanty, W., Yamada, Y. & Akiyama, S. (1995). Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 55: 1687–1690.
Miyazono, K., Okabe, T., Urabe, A., Takaku, F. & Heldin, C. H. (1987). Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 262: 4098–4103.
Moghaddam, A. & Bicknell, R. (1992). Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 31: 12141–12146.
Moolten, F. L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276–5281.
Moolten, F. L. & Wells, J. M. (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82: 297–300.
Mullen, C. A., Kilstrup, M. & Blaese, R. M. (1992). Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 89: 33–37.
Nishida, M., Hino, A., Mori, K., Matsumoto, T., Yoshikubo, T. & Ishitsuka, H. (1996). Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 19: 1407–1411.
O’Brien, T. S., Fox, S. B., Dickinson, A. J., Turley, H., Westwood, M., Moghaddam, A., Gatter, K. C., Bicknell, R. & Harris, A. L. (1996). Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 56: 4799–4804.
Parker, W. B., King, S. A., Allan, P. W., Lee, Bennett Jr L., Secrist, JA III, Montgomery, J. A., Gilbert, K. S., Waud, W. R., Wells, A. H., Gillespie, G. Y. & Sorscher, E. J. (1997). In vivo gene therapy with E. coli purine nucleoside phosphorylase. Hum Gene Ther 8: 1637–1644.
Patterson, A. V., Zhang, H., Moghaddam, A., Bicknell, R., Talbot, D. C., Straford, I. J. & Harris, A. L. (1995). Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-desoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 72: 669–675.
Rustum, Y. M., Harstrick, A., Cao, S., Vanhoefer, U., Yin, M. B., Wilke, H. & Seeber, S. (1997). Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 15: 389–400.
Schwartz, E. L., Baptiste, N., O’Connor, C. J., Wadler, S. & Otter, B. A. (1994). Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase. Cancer Res 54: 1472–1478.
Schwartz, E. L., Baptiste, N., Wadler, S. & Makower, D. (1995). Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 270: 19073–19077.
Schwartz, E. L., Wan, E., Wang, F. S. & Baptiste, N. (1998). Regulation of expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human colon carcinoma cells. Cancer Res 58: 1551–1557.
Shaw, J., Smillie, R. H., Miller, A. E. & MacPhee, D. G. (1988). The role of blood platelets in nucleoside metabolism: regulation of thymidine phosphorylase. Mutat Res 200: 117–131.
Sobrero, A. F., Aschele, C. & Bertino, J. R. (1997). Fluorouracil in colorectal cancer. A tale of two drugs: implications for biochemical modulation. J Clin Oncol 15: 368–381.
Sumizawa, T., Furukawa, T., Haraguchi, M., Yoshimura, A., Takeyasu, A., Ishizawa, M., Yamada, Y. & Akiyama, S. (1993). Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J Biochem 114: 9–14.
Trinh, Q. T., Austin, E. A., Murray, D. M., Knick, V. C. & Huber, B. E. (1995). Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 55: 4808–4812.
Wei, M. X., Tamiya, T., Chase, M., Boviatsis, E. J., Chang, T. K. H., Kowall, N. W., Hochberg, F. H., Waxman, D. J., Breakefield, X. O. & Chiocca, E. A. (1994). Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 5: 969–978.
Yoshimura, A., Kuwazuru, Y., Furukawa, T., Yoshida, H., Yamada, K. & Akiyama, S. (1990). Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. Biochim Biophys Acta 1034: 107–113.
Zimmerman, M. & Seidenberg, J. (1964). Deoxyribosyl transfer. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissue. J Biol Chem 230: 2618–2621.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Evrard, A., Cuq, P., Ciccolini, J. et al. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5′-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 80, 1726–1733 (1999). https://doi.org/10.1038/sj.bjc.6690589
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690589
Keywords
This article is cited by
-
Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer
The Pharmacogenomics Journal (2020)
-
The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells
Gastric Cancer (2019)
-
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Nature Reviews Gastroenterology & Hepatology (2016)
-
Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells
Cancer Chemotherapy and Pharmacology (2015)
-
The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy
Acta Pharmacologica Sinica (2014)